Immunomodulation Therapy – Clinical Relevance of Bacterial Lysates OM-85

Giovanni A Rossi,1 Susanna Esposito,1 Wojciech Feleszko,4 Giovanni Melioli,4 Dario Olivieri,3 Giorgio Piacentini,4 Francesco Scaglione6 and Donata Vercelli1

1. Giannina Gaslini Institute, Genoa, Italy; 2. Pediatric Clinic, Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy; 3. Medical University of Warsaw, Warsaw, Poland; 4. Humanitas University, Milan, Italy; 5. University of Parma, Parma, Italy; 6. University of Verona, Verona, Italy; 7. University of Milan, Milan, Italy; 8. University of Arizona, Tucson, AZ, US

DOI: https://doi.org/10.17925/ERPD.2019.5.1.17

Respiratory tract infections (RTIs) affect children and adults with chronic respiratory conditions throughout the world. As RTIs can often recur, they confer a significant morbidity and mortality burden and represent an important unmet medical need. Studies have shown that the bacterial lysates OM-85 can activate both innate and adaptive immune responses via maturation of gut mucosal dendritic cells, resulting in the homing of immune cells to lymphoid tissue in the lungs and subsequent antibody production. In line with these mechanistic properties, OM-85 has demonstrated clinical efficacy in preventing RTIs in several clinical studies, as well as exacerbations of various respiratory conditions such as asthma, chronic bronchitis, chronic obstructive pulmonary disease and chronic rhinosinusitis. In addition, clinical study and pharmacovigilance data show that OM-85 is not only well tolerated in both adult and paediatric populations, but also can be used in combination with vaccines to provide additional benefits with a manageable risk profile. As such, OM-85 represents a valuable addition to the therapeutic landscape for recurrent or chronic respiratory conditions.

Keywords
Bacterial lysates, immunomodulation therapy, OM-85

Disclosures: Giovanni A Rossi has received honoraria for his scientific support from Abzeév Inc, Chiesi Farmaceutici, Lucifarma and OM Pharma (a Vifor Pharma Group company). Susanna Esposito has received research grants from OMG, GlaxoSmithKline, Sanofi, OM Pharma (a Vifor Pharma Group company) and honoraria for her scientific support from AstraZeneca, MSD, Sanofi and Vifor Pharma. Wojciech Feleszko has worked as a speaker for Angelini, Bayer AG, GlaxoSmithKline, Mylan, Nutricia, Sandoz and OM Pharma (a Vifor Pharma Group company), and has received research grants from Philips and Biomed. Giovanni Melioli is an advisor to Bruschetti SRL, Lallemand Pharma SAS, Ettek SPA and DASIT SpA and has received honoraria for scientific support from OM Pharma (a Vifor Pharma Group company) and OM Pharma (a Vifor Pharma Group company in Asia). Giorgio Piacentini has received honoraria for scientific support from Chiesi, Merck Sharp & Dhome, Vifor Pharma, and Pediatrica. Donata Vercelli has received research grants from The National institutes of Health, OM Pharma (a Vifor Pharma Group company), and Johnson & Johnson. Dario Olivieri and Francesco Scaglione have no conflicts of interest to declare.

Acknowledgements: Editorial assistance was provided by Stuart Wakens of Touch Medical Communications and funded by OM Pharma, a Vifor Pharma Group company.

Review Process: Double-blind peer review.

Compliance with Ethics: This article expresses the opinions of the authors based on the results of a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: All named authors meet the international Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Received: 13 February 2019
Accepted: 24 June 2019
Citation: European Respiratory & Pulmonary Diseases. 2019;5(1):T7–T23
Corresponding Author: Giovanni A Rossi, G Gaslini Hospital, Largo G Gaslini 4, 16147 Genoa, Italy. E: giovannirossi@gaslini.org

Support: This article was drafted using content from an Advisory Board meeting organised by OM Pharma, a Vifor Pharma Group company. The publication of this article was supported by OM Pharma, a Vifor Pharma Group company. The views and opinions expressed are those of the authors.

Acute respiratory tract infections (RTIs) affect children and adults with chronic respiratory conditions throughout the world, and are associated with significant morbidity and mortality.1 Acute RTIs are one of the leading causes of mortality in both children and adults, with an estimated 3.5–4 million deaths per year attributed to both acute upper and lower RTIs.2 Recurrent RTIs are especially common in young children, affecting up to 25% of children <1 year of age and 18% of children 1–4 years of age.3 Paediatric RTIs also incur substantial healthcare costs; they frequently cause complications that necessitate multiple medical visits, accounting for nearly half of all paediatric consultations in developed countries, and are among the leading causes of paediatric hospital admissions in the USA.4 Furthermore, although many RTIs have viral aetiology, they are still a leading cause of antibiotic prescriptions, thereby contributing to the development of antibiotic resistance and further increasing healthcare costs.5 Overall, despite the availability of healthcare in developed countries, RTIs still exert a substantial clinical and economic burden and represent a clear unmet medical need.1

Prevention of RTIs can be difficult, as the risk factors are many and varied, including sociodemographic (partial immunisation, overcrowding), nutritional (malnutrition) and environmental aspects, as well as clinical risk factors, such as minor immunodeficiencies.2,6 However, the use of immunostimulants or immunomodulator therapies may provide an alternative therapeutic option that is complementary to vaccination.6

Bacterial lysates, such as OM-85, are produced by chemical or mechanical lysis of specific bacterial cultures. As such, they contain conserved pathogen-associated molecular patterns (PAMPs) for these bacteria, which have the potential to activate the cellular constituents of innate and adaptive non-specific loco-regional immune responses.2–4 This can lead to the induction of not only specific, but also non-specific loco-regional immune responses, with polyclonal production of immunoglobulins.6–13 Therefore, lysates of bacteria from the respiratory tract may provide clinical benefit in patients with recurrent RTIs, regardless of the viral or bacterial aetiology, in different RTIs.
Table 1: Summary of key bacterial lysates and their compositions

| OM-85* | Ismigen1 | Irudon2 | IRS-1P | Luivac1 | PulmonarOM |
|--------|---------|---------|--------|---------|------------|
| Chemical lysate of 21 bacterial strains from 8 bacterial species | Mechanical lysate of 13 bacterial strains from 8 bacterial species | Bacterial lysate from 13 bacterial species | Bacterial lysate from 12 bacterial species | Bacterial lysate from 7 bacterial species | Bacterial lysate from 9 bacterial species |
| – Streptococcus pneumoniae | – Streptococcus pyogenes | – Lactobacillus acidophilus pneumoniae | – Streptococcus pneumoniae | – Haemophilus influenzae |
| – Streptococcus pyogenes | – Streptococcus pyogenes | – Lactobacillus debrueckii | – Staphylococcus aureus | – Staphylococcus aureus |
| – Staphylococcus viridans | – Staphylococcus aureus | – Lactobacillus helveticus | – Enterococcus faecium | – Neisseria subflava |
| – Staphylococcus aureus | – Streptococcus pyogenes | – Lactobacillus fermentum | – Neisseria meningitidis | – Neisseria perflava |
| – Klebsiella pneumoniae | – Streptococcus anginosus | – Streptococcus pyogenes | – Klebsiella pneumoniae | – Moraxella catarrhalis |
| – Klebsiella pneumoniae | – Staphylococcus aureus | – Enterococcus faecalis | – Moraxella catarrhalis | – Haemophilus influenzae |
| – Moraxella catarrhalis | – Enterococcus faecalis | – Enterococcus faecalis | – Streptococcus pneumoniae | – Streptococcus pneumoniae |
| – Haemophilus influenzae | – Klebsiella pneumoniae | – Streptococcus pyogenes | – Streptococcus pyogenes | – Streptococcus mitis |
| – Haemophilus influenzae | – Staphylococcus aureus | – Klebsiella pneumoniae | – Moraxella catarrhalis | – Branhamella catarrhalis |

*Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Vaxoral®, Paxoral®, Immubron®, Bromunyl®, Bactovax®, PIR-05, PMBL, IRS-307, KWS0020.

OM-85 is the product of alkaline lysis of 21 strains of eight species of common bacterial respiratory tract pathogens: Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Klebsiella ozaeae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans and Moraxella catarrhalis.10 The active ingredients of OM-85 retain their activity following gastric transit, as well as their cell activation capacity following gastric-buffer incubation.10 The resultant non-specific potentiation of the immune system may help to protect against both viral and bacterial respiratory infections and, as discussed in more detail later, may also provide additional clinical benefits in inflammatory conditions such as asthma and COPD by balancing immune responses via downregulation of Th2-mediated airway hyperreactivity/inflammation and stimulating the release of anti-inflammatory cytokines.10,11

OM-85 – mechanism of action

The rationale for the use of orally administered immunomodulators for the prevention of RTIs is focused around the sampling of specific antigens by microfold (M) cells and dendritic cells in gut-associated lymphoid tissue (GALT).10 In the case of OM-85, antigen sampling by M cells in GALT Peyers’s patches in the small intestine initiates mucosal immunity responses, allowing for transport of microbial antigens across the epithelial cell layer from the gut lumen to the lamina propria where interactions with dendritic cells can take place (Figure 1A).10,11 This leads to maturation of mucosal dendritic cells into antigen presenting cells, which initiate immune cascades that involves the downstream activation of cellular constituents of both the innate and adaptive branches of the immune system.12,13 These downstream events include:

- the activation of monocytes and natural killer cells;
- the activation of T cells (T-helper [Th] 1 cells, T-regulatory [Treg] cells and cytotoxic CD8+ cells);
- the expression of anti-microbial peptides in epithelium and mucosa;
- the activation of macrophages;
- the migration of polymorphic neutrophils to the lung;
- the migration of polymorphic neutrophils to the lung;
- the migration of polymorphic neutrophils to the lung;
- the migration of polymorphic neutrophils to the lung;
- the migration of polymorphic neutrophils to the lung;
Table 2: Summary of available clinical study data for key bacterial lysates

|                 | OM-85* | Ismigen† | Imudon‡ | IRS-19 | Luivac§ | PulmonarOM |
|-----------------|--------|----------|---------|--------|---------|------------|
| Clinical trials | +++    | +        | +/-     | +      | +++     | –          |
| Safety          | +++    | +        | +       | +      | +++     | +          |
| Convenience dosing in children | +++ | +/- | +/- | + | +++ | ++ |
| Composition     | +++    | +++      | +++     | +++    | ++      | ++         |
| Post-marketing experience (global) | +++ | – | – | – | + | – |
| GOLD reference | +      | –        | –       | –      | –       | –          |
| EPOS recommendation | Grade A, level 1b | – | – | – | – | – |
| 'A' quality Cochrane studies | 4 | – | – | – | – | – |

*Broncho-Vaxom®, Broncho-Munin®, Ommunal®, Vaxoral®, Paxoral®, Immubron®, Bromunyl®, Bactovax®, PIR-05, PMBL, IRS-307, LW50020, immunobalt, paspat, munostin

EPOS = European position paper on rhinosinusitis and nasal polyps; GOLD = global initiative for chronic obstructive lung disease.

Figure 1: Immunomodulatory mechanism of action of OM-85†

(A) OM-85 acts as a PAMP that causes maturation of mucosal dendritic cells in gut-associated immune tissue Peyer’s patches (via M cells), which then cause downstream activation of cellular constituents of innate and adaptive mucosal immune responses. These downstream events include: (i) the activation of monocytes and natural killer cells; (ii) the activation of T cells (Th1 cells, Treg cells and cytotoxic CD8+ cells); (iii) the expression of anti-microbial peptides in epithelium and mucosa; (iv) the activation of macrophages; (v) the migration of polymorphonuclear neutrophils to the lung; (vi) the expression of B-cell and antiviral Th1-related cytokines, and (vii) B-cell maturation (leading to an increase in serum and airway immunoglobulins).

(B) OM-85 also results in the promotion of immune system maturation in children via downregulation of Th2 and restoration of Th1/Th2 imbalances through activation of Treg cells.

Table 2: Summary of available clinical study data for key bacterial lysates

|                 | OM-85* | Ismigen† | Imudon‡ | IRS-19 | Luivac§ | PulmonarOM |
|-----------------|--------|----------|---------|--------|---------|------------|
| Clinical trials | +++    | +        | +/-     | +      | +++     | –          |
| Safety          | +++    | +        | +       | +      | +++     | +          |
| Convenience dosing in children | +++ | +/- | +/- | + | +++ | ++ |
| Composition     | +++    | +++      | +++     | +++    | ++      | ++         |
| Post-marketing experience (global) | +++ | – | – | – | + | – |
| GOLD reference | +      | –        | –       | –      | –       | –          |
| EPOS recommendation | Grade A, level 1b | – | – | – | – | – |
| 'A' quality Cochrane studies | 4 | – | – | – | – | – |

*Broncho-Vaxom®, Broncho-Munin®, Ommunal®, Vaxoral®, Paxoral®, Immubron®, Bromunyl®, Bactovax®, PIR-05, PMBL, IRS-307, LW50020, immunobalt, paspat, munostin

EPOS = European position paper on rhinosinusitis and nasal polyps; GOLD = global initiative for chronic obstructive lung disease.

Figure 1: Immunomodulatory mechanism of action of OM-85†

(A) OM-85 acts as a PAMP that causes maturation of mucosal dendritic cells in gut-associated immune tissue Peyer’s patches (via M cells), which then cause downstream activation of cellular constituents of innate and adaptive mucosal immune responses. These downstream events include: (i) the activation of monocytes and natural killer cells; (ii) the activation of T cells (Th1 cells, Treg cells and cytotoxic CD8+ cells); (iii) the expression of anti-microbial peptides in epithelium and mucosa; (iv) the activation of macrophages; (v) the migration of polymorphonuclear neutrophils to the lung; (vi) the expression of B-cell and antiviral Th1-related cytokines, and (vii) B-cell maturation (leading to an increase in serum and airway immunoglobulins).

(B) OM-85 also results in the promotion of immune system maturation in children via downregulation of Th2 and restoration of Th1/Th2 imbalances through activation of Treg cells.

B = B cell; DC = dendritic cell; GALT = gut-associated immune tissue; Ig = immunoglobulin; Mc = macrophage; Mo = monocyte; NK = natural killer cell; PAMPS = pathogen-associated molecular patterns; PC = plasma cell; PMN = polymorphonuclear neutrophil; PPs = Peyer’s patches; sig = secretory immunoglobulin; T = T cell; Th = T helper cell; TLR = toll-like receptor; Treg = T regulatory cell.
the expression of B-cell and antiviral Th1-related cytokines (via selective induction of nuclear factor-kB); B-cell maturation (leading to an increase in serum and airway immunoglobulins); and the promotion of immune system maturation in children via downregulation of Th2 and restoration of Th1/Th2 imbalance through activation of Treg cells (Figure 1B).10–12

This, in turn, may result in the homing of immune cells to bronchial-associated lymphoid tissue in the lungs and subsequent polyclonal antibody production, facilitating immune responses against viral and bacterial RTIs.6,11 In addition, OM-85 has been shown to have broader immunomodulatory effects. These include:

- an antiviral effect via the induction of interferon-α and interferon-β and a dual effect on interleukin (IL)-1 production (downregulating IL-1β during an inflammatory state, thereby controlling inflammation, but inducing pro-IL1β in the absence of a strong inflammatory state), indicating that OM-85 favours a protective primed immunological state while dampening inflammasome activation in specific conditions;10,14
- the stimulation of cytokines, such as IL-6 and tumour necrosis factor-alpha (TNF-α), indicating an enhanced clearance ability of macrophages against invading bacteria;19
- increasing the levels of CD4+, CD25+, Foxp3+ and Tregs in airway mucosal tissues, attenuating airway inflammation and hyperresponsiveness;20 and
- the selective induction of NF-κB and MAPK in dendritic cells, thereby upregulating chemokines involved in the migration of macrophages and neutrophils, as well as upregulating B-cell activating cytokines such as IL-10, which may control excessive expression of pro-inflammatory mediators and tissue damage in patients with COPD.21

In summary, the effects of OM-85 have been well characterised and its mode of action is sophisticated and multifactorial, distinct from the antigen-specific action of vaccines (i.e., the production of specific antibodies by B cells).10–11

OM-85 – safety profile

OM-85 has a favourable safety profile that is supported by nearly 40 years of clinical experience and pharmacovigilance monitoring.22 Cumulative pharmacovigilance data from 1979 up to 31 October 2017 show that from an estimated OM-85 exposure of ~100 million patients, only 1,974 adverse event reports (unsolicited and solicited) have been received and registered in the safety database (OM Pharma; data on file). From this safety database, important identified risks were shown to be limited to hypersensitivity reactions (Standardised MedDRA Query), with 538 cases reported. The majority of these hypersensitivity reactions were classified as non-serious (~85%) and were localised to the skin (e.g. pruritus, rash, urticaria, erythema, hypersensitivity; these accounted for 57% of all reports). In total, 28 severe adverse cutaneous reaction reports were registered in the safety database (OM Pharma; data on file), with only three instances of toxic epidermal necrolysis or Stevens-Johnson Syndrome reported in patients receiving OM-85 in nearly 40 years. Further, no relationship with OM-85 administration and these events was established, and therefore no safety signal was validated.

These data support the findings from placebo-controlled clinical trials, where OM-85 has demonstrated a favourable safety profile (similar to that of placebo in most studies) in the prevention of RTIs in children,10,23 the management of atopic dermatitis in children,24 and the prevention of exacerbations in adults and the elderly with chronic lung inflammatory disease such as chronic bronchitis and/or COPD.22,28 Indeed, a meta-analysis of data from eight clinical trials investigating OM-85 for the secondary prevention of recurrent RTIs reported similar rates to placebo for minor adverse events (17.7% versus 18.2%; OM-85 versus placebo, respectively), serious adverse events (1.0% versus 0.5%), and study withdrawals due to adverse events (1.3% versus 0.7%).29 No causal relationship was established for any of these adverse events, no laboratory abnormalities were reported and no deaths attributed to study medication.30

Controversies – potential interference with vaccines

There are two main concerns that have been raised regarding bacterial lysates and vaccinations: that bacterial lysates, such as OM-85, might contribute to a reduction in vaccination coverage rates, as they contain bacterial antigens such as S. pneumoniae and H. influenzae and could therefore be incorrectly regarded as a substitute for vaccines against these pathogens; and that the administration of bacterial lysates alongside vaccines may impact the immunogenicity and/or tolerability of the vaccine itself.

With regard to the potential reduction in vaccination rates, there is no robust evidence of immunostimulants or immunomodulators being prescribed as an alternative to active immunisation in Italy or other countries. Indeed, bacterial lysates are typically used to reduce the risk of respiratory infection as a complementary strategy to other preventative measures such as vaccination.31 As such, the authors feel that a reduction in vaccination coverage rates due to OM-85 use would be unlikely.

With regard to the impact on the immunogenicity and/or tolerability of vaccines, the mechanism of action of OM-85 is distinct to the antigen-specific effect of vaccines (non-specific potentiation of the immune system versus production of specific antibodies by memory B cells, respectively),10 indicating that any interference is unlikely. This hypothesis is supported by the results of a prospective, randomised, single-blind study conducted by Esposito et al. of children affected by recurrent RTIs.29 In total, 68 children 36–59 months of age were vaccinated with an inactivated influenza vaccine either with (n=33) or without (n=35) concomitant OM-85 (administered using a standard 3 x 10³ dosing regimen [see clinical evidence section for further details]).31 Overall, the inactivated influenza vaccine was shown to be effective in stimulating an immune response to help prevent infection in children.31 Co-administration of the vaccine with OM-85 was found to have no significant effect on influenza vaccine-induced seroconversion or seroprotection rates, geometric mean titres, the number of dendritic cells or the presence of plasmacytoid dendritic cells.29 In addition, OM-85 did not significantly change the pool of memory B cells that produce immunoglobulin G and immunoglobulin M antibodies against influenza antigens, both of which were significantly increased post-vaccination (3–4 fold increase, p<0.01 for both immunoglobulin isotypes).30 However, compared with the administration of vaccine alone, respiratory morbidity and antibiotic use was significantly reduced in patients receiving both vaccine and OM-85 compared with patients receiving only vaccine, suggesting an added therapeutic benefit when combining the two complementary preventive measures (Figure 2).31 The incidence of adverse events was nearly similar between the OM-85 and no OM-85 treatment groups (15.2% versus 20.0%, respectively), both for local reactions (12.1% versus 17.1%) and systemic reactions (6.0% versus 11.4%), with no serious adverse events reported.27 This demonstrates the favourable tolerability profile of OM-85 in combination with an inactivated influenza vaccine. Similar results have been reported in a study of 396 elderly patients (>65 years of age) receiving influenza vaccination with OM-85 (n=147) or without OM-85 (n=143).28
In conclusion, it is the authors’ opinion that vaccination schedules for measles, mumps, rubella and/or varicella (MMR/MMRV) origin.

Further, based on present general knowledge, preclinical and clinical pharmacovigilance surveillance (OM Pharma; data on file; cumulative administration of OM-85 and influenza vaccines in post-marketing no safety issues have been reported relating to the concomitant use of OM-85 and influenza vaccines alone). Supporting the clinical study findings, no significant difference between groups was observed in circulating immunoglobulin concentration or intercurrent medical events, with no specific side-effects reported. In addition, a 28% reduction in both lower RTIs and antibiotic use was reported with OM-85 (compared with influenza vaccination alone). Supporting the clinical study findings, no safety issues have been reported relating to the concomitant administration of OM-85 and influenza vaccines in post-marketing pharmacovigilance surveillance (OM Pharma; data on file; cumulative pharmacovigilance safety database from 1979 to 31 October 2017). Further, based on present general knowledge, preclinical and clinical studies, and post-marketing surveillance, there does not appear to be any evidence of interaction between OM-85 and any vaccines, of either bacterial (e.g. Haemophilus influenzae, Streptococcus pneumoniae) or viral (e.g. trivalent or tetravalent live attenuated vaccines, such as measles, mumps, rubella and/or varicella [MMR/MMRV]) origin.

In children, there are currently only guidelines for the treatment of specific paediatric conditions (such as otitis media), and while most of these recommend avoiding antibiotic overuse in the treatment of paediatric RTIs by adopting preventive measures, they do not specify what these measures might be. Clinical evidence indicates that OM-85 could address both of these issues, by reducing the frequency of RTIs and antibiotic use. Additionally, clinical benefits have also been reported for recurrent otitis media and acute bacterial tonsillitis. Dosing regimens vary between these studies, but the most commonly used regimen involves administering one capsule (containing 3.5 mg of lyophilised bacterial lysates) every morning for the first 10 days of each month for 3 months. A second round of 3 x 10 doses can also be administered 6 months after the first dose. A meta-analysis, as well as other combined study analyses, supports the results of these individual clinical trials, showing that OM-85 can significantly and consistently reduce the incidence of recurrent paediatric RTIs by 36% and that OM-85 provides the greatest benefit in preschool children and patients with a history of very frequent RTIs. A second round of 3 x 10 doses can also be administered 6 months after the first dose. A meta-analysis, as well as other combined study analyses, supports the results of these individual clinical trials, showing that OM-85 can significantly and consistently reduce the incidence of recurrent paediatric RTIs by 36% and that OM-85 provides the greatest benefit in preschool children and patients with a history of very frequent RTIs. In addition, by preventing RTIs and/or bacterial complications, OM-85 has also been shown to reduce antibiotic use and provide cost-savings for the community and healthcare services.

Despite the burden exerted by recurrent RTIs, there are no formal international guidelines for the treatment and management of recurrent RTIs per se. In children, there are currently only guidelines for the treatment of specific paediatric conditions (such as otitis media), and while most of these recommend avoiding antibiotic overuse in the treatment of paediatric RTIs by adopting preventive measures, they do not specify what these measures might be. Clinical evidence indicates that OM-85 could address both of these issues, by reducing the frequency of RTIs and antibiotic use. Additionally, clinical benefits have also been reported for recurrent otitis media and acute bacterial tonsillitis. Dosing regimens vary between these studies, but the most commonly used regimen involves administering one capsule (containing 3.5 mg of lyophilised bacterial lysates) every morning for the first 10 days of each month for 3 months. A second round of 3 x 10 doses can also be administered 6 months after the first dose. A meta-analysis, as well as other combined study analyses, supports the results of these individual clinical trials, showing that OM-85 can significantly and consistently reduce the incidence of recurrent paediatric RTIs by 36% and that OM-85 provides the greatest benefit in preschool children and patients with a history of very frequent RTIs. In addition, by preventing RTIs and/or bacterial complications, OM-85 has also been shown to reduce antibiotic use and provide cost-savings for the community and healthcare services.

Controversies – potential risks in atopic or asthmatic patients

As described earlier, there is an established mechanistic and clinical rationale for the use of non-specific immunomodulators as prophylaxis against RTIs. In addition, the immunoregulatory properties of OM-85 support its use in patients with an atopic condition such as poorly controlled asthma; the OM-85-induced modulation of Treg cells could potentially lead to more efficient viral clearance and a downregulation of inappropriate Th2-associated immune responses, which are central to the airway hyper-responsiveness and inflammation during asthma exacerbations. In line with this hypothesis, a number of studies have shown that prophylaxis with OM-85 in paediatric patients with a history of recurrent wheezing or asthma can significantly reduce the incidence of exacerbations triggered by infections and wheezing episodes (by ~30–50%; p<0.05), RTIs (by ~30–40%; p<0.01), and antibiotic use (44% [days]; p<0.01). In addition, OM-85 was shown to have a favourable safety profile in the studies that reported safety data, with adverse events occurring at a similar incidence to placebo/control groups (~5–10%) and no severe events or events leading to treatment discontinuation reported.

Clinical evidence and relevance of OM-85 in the prevention of respiratory tract infections

Respiratory tract infections in the paediatric population

Clinical study data have shown OM-85 to be effective for the prevention of RTIs in children for at least 6 months (up to ~35–40% reduction) irrespective of aetiology. Additional clinical benefits have also been reported for recurrent otitis media and acute bacterial tonsillitis. Dosing regimens vary between these studies, but the most commonly used regimen involves administering one capsule (containing 3.5 mg of lyophilised bacterial lysates) every morning for the first 10 days of each month for 3 months. A second round of 3 x 10 doses can also be administered 6 months after the first dose. A meta-analysis, as well as other combined study analyses, supports the results of these individual clinical trials, showing that OM-85 can significantly and consistently reduce the incidence of recurrent paediatric RTIs by 36% and that OM-85 provides the greatest benefit in preschool children and patients with a history of very frequent RTIs. In addition, by preventing RTIs and/or bacterial complications, OM-85 has also been shown to reduce antibiotic use and provide cost-savings for the community and healthcare services.

Based on available clinical data and meta-analyses, the authors propose three key recommendations for the use of OM-85 in the prevention of recurrent RTIs in paediatric patients:

- that OM-85 is considered in children 2–6 years of age who are at the highest risk of RTIs, as OM-85 appears to confer the greatest benefit in these patients (Figure 3);
- that OM-85 is considered for the prevention of viral RTIs, as its clinical efficacy is not limited to the prevention of bacterial RTIs; and
- that the use of OM-85 is not limited by the concurrent administration of vaccines.

Adult population

COPD is a major public health challenge and a leading cause of chronic mortality and morbidity, which is predicted to become the third largest global cause of death by 2020. The main goals for the treatment of
COPD are to reduce symptoms and prevent future exacerbations (acute episodes of disease worsening), which are associated with a worse prognosis, reduced quality of life and increased mortality risk.43 Because of the increased morbidity and mortality risk, patients with COPD who experience frequent exacerbations require additional treatment beyond symptomatic control.

As the large majority (~50–80%) of COPD exacerbations are associated with bacterial or viral respiratory infections,44 targeting specific molecular pathways to prevent viral/bacterial infection and reduce inflammation could therefore help prevent or mitigate COPD exacerbations. As such, OM-85 provides a complementary and effective therapeutic option for adults with COPD who experience frequent exacerbations (via modulation of the lung immune response), potentially reducing hospitalisations and the use of antibiotics.45 Data from clinical trials support this hypothesis, with several studies reporting significant reductions in exacerbations, decreased severity of exacerbations and reduced antibiotic use/hospitalisation in patients with COPD or chronic bronchitis receiving OM-85 treatment.27,28,46–49 In addition, a meta-analysis by Pan et al reported OM-85 to be associated with a 20% reduction in COPD exacerbations and a 39% reduction in antibiotic use.50 However, no significant effect was observed on the severity of exacerbations or duration of hospitalisations.50 Nevertheless, as healthcare costs and resource utilisation associated with COPD and other chronic respiratory conditions are high, incorporating OM-85 into an integrated care programme has the potential to reduce these costs and optimise disease management and patient outcomes.51,52 Indeed, OM-85 is included and recommended (Grade A) in treatment guidelines for acute and chronic rhinosinusitis in adults without nasal polyps, and could also provide benefits in these patients.53,54 In addition, the use of bacterial lysates is mentioned in the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) document with respect to the potential benefits of reducing exacerbations in COPD.43

Overall, considering the available clinical data and meta-analyses, the key recommendations and conclusions based on author consensus are:

- that OM-85 may show the greatest treatment response in those with a high frequency of exacerbations (i.e., those with the greatest risk of morbidity and mortality); and
- that OM-85 could provide a cost-effective means of reducing COPD exacerbations.

**Clinical relevance of OM-85 within the context of increasing antibiotic resistance**

Antibiotic resistance is an increasing problem, with new strains of resistant bacteria continuing to emerge and ~25,000 deaths attributed to specific antibiotic resistant bacteria in the EU in 2007.55,56 With few alternative antibiotic options available and/or in development, there are only two viable approaches to overcome this problem: improving the use of current antibiotics and reducing the number of infections. Unfortunately, the overuse and misuse of antibiotics in paediatric patients is still a common issue despite attempts to increase awareness and education.57 As such, reducing the number of infections (and in turn antibiotic use) may be the most viable option. Furthermore, antibiotic treatment is an important perturbing factor of the microbial equilibrium of both the gut and respiratory microbiota throughout life.24 In children this has been shown to decrease the abundance of presumed beneficial commensal bacteria in the upper respiratory tract, which might increase the risk of RTIs following antibiotic treatment.44 OM-85 may help address these issues, as it represents a way to reduce antibiotic use, especially in patients with a higher risk of RTIs requiring antibiotics, such as those with COPD.28,29,40,48,50

**Immunomodulatory properties of OM-85 – current understanding and future perspectives**

Because immunological responses are highly complex, the targeting of multiple molecules/pathways (rather than a single molecule/pathway) is usually required in order to achieve a beneficial immunomodulatory effect. OM-85 targets multiple pathways and has a broad range of immunological effects, including Treg cell expansion in the airways.10,60 As such, it is hypothesised that OM-85 may promote a re-organisation of gut and lung microbial communities, improving cross-talks with immune effectors that favour immune homeostasis and reducing disease exacerbations and antibiotic use.58 However, while our understanding of microbial ecology has increased dramatically over recent years, much remains to be understood about how different microbial groups influence various arms of host immune defence, and further studies are required to characterise the effect of OM-85 treatment on these interactions.59,61

**Discussion**

While OM-85 is classified as part of the bacterial lysates family, it has been shown to possess its own distinct and multifactorial mode of action, causing maturation and activation of gut mucosal dendritic cells, homing of immune cells to lymphoid tissue in the lungs and activation of cellular constituents of innate and adaptive mucosal immune responses.54,55 Clinical study and pharmacovigilance data have shown that OM-85 is well tolerated in both adult and paediatric populations and that it can be used in combination with vaccines with a manageable risk profile. Clinical studies have shown that OM-85 provides clinical benefits in various respiratory conditions such as asthma, chronic bronchitis, COPD and chronic rhinosinusitis, as well as clinical efficacy in preventing both...
viral and bacterial RTIs and reducing antibiotic use. Based on the evidence to date, the authors believe that OM-85 can provide the most benefit to paediatric patients by:

- considering OM-85 use in children 2–6 years of age who are at the highest risk of RTIs;
- considering OM-85 for the prevention of viral RTIs as well as bacterial RTIs; and
- not limiting the use of OM-85 during administration of vaccines. Preclinical evidence clarifying the mechanism of action of OM-85, S–D together with recent clinical evidence, 18,25,36 indicate that its use could also be extended to the prevention of recurrent paediatric infection-induced wheezing or asthma attacks, as well as providing benefits for patients with non- atopic conditions such as chronic rhinosinusitis and COPD (in adults).27,28,41,63,14

Overall, OM-85 represents a valuable addition to the therapeutic landscape for these conditions and may be an effective tool not only for specialists (paediatricians, pulmonologists, ear, nose and throat), but also for general practitioners.

Conclusions

In conclusion, there is growing mechanistic and clinical evidence supporting both the ability of OM-85 to promote immune homeostasis and the benefits of OM-85 therapy in various respiratory conditions such as asthma, COPD, chronic rhinosinusitis and in the prevention of RTIs. Additional research is required to further characterise the properties of OM-85 and investigate the therapeutic benefit in specific patient populations or respiratory conditions.

References

1. Schaadt UB, Espósito S, Rati CH. Diagnosis and Management of Recurrent Respiratory Tract Infections. In: A Practical Guide. Arch Pediatr Infect Dis. 2016;4:e01309.
2. Bosco AA, Bieniek G, Tecrim K, et al. Viral and bacterial respiratory infections in first month of life. Pediatr Infect Dis. 2013;e160365.
3. Schunck H. Global Respiratory Societies, The Global Impact of Respiratory Disease - Second Edition. Sheffield European Respiratory Society. Available at: www.wrh.org/gps/ global_impact_of_respiratory_disease.pdf (accessed 3 February 2019).
4. Veil UZ, Klemmer KP, Raebel MA, et al. Recent trends in inpatient hospitalization for children. Pediatrics. 2014;133:375-85.
5. Schenke A, Lichter MB, Schumacher SB, Pradpeek Kumui J, et al. Modifiable risk factors for acute lower respiratory tract infections. Indian Pediatr. 2007;44:47-72.
6. Fazalpuro T, Einhorn P, Rauch M, et al. Prevalence and clinical course of viral upper respiratory tract infections in in-hospital uncompromised pediatric patients with malignancies or after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2012;34:442–45.
7. Retrospective study by Zogg K, Zimmermann KO, et al. Detection of multiple respiratory viruses associated with mortality and severity of illness in children. Pediatr Crit Care Med. 2015;16:256-1.
8. Feltesko W, Ružmucký M, Zalebski BM. Non-specific immune stimulation in respiratory tract infections. Separating the wheat from the chaff. Paediatr Respir Rev. 2014;15:20-6.
9. Bradem F, Taranent F, Etholigne V, et al. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis. 2007;2:335–45.
10. Espósito S, Soto-Martínez ME, Feléusko W, et al. Nonspecific, immunomodulatory bacterial extracts in respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2014;14:9-14.
11. Rozy A, Chrostowska-Wynimko J. Bacterial immunostimulants and viral infections. A role of protection and clinical application in respiratory diseases. Pneumologii Alergol Pol. 2008;76:353-9.
12. Krasnorodski D, Dziedzicka M, Felteko W. Immunomodulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Allergy Asthma Immunol. 2015;14:364-9.
13. Manolova V, Flace A, Jancarić F, et al. Bismarkers induced by the immunostimulatory bacterial extract OM-85: unique roles for Peyer’s patches and intestinal epithelial cells. J Clin Immunol. 2017;49:49.
14. Vaughan Williams EM, Miller JS, Campbell TJ. Electrophysiological effects of levobule on arterial, venous and pulmonary cells, in hamster and hypoxia. Cardiovasc. Res. 1982;16:233-9.
15. Hetin-Salminaa A, Vartia A, Vesalainen K, et al. NSAI use and acute respiratory infection as a first medical contact in the general population: a nationwide case-control study from Finland. Eur J Public Health. 2017;27:167–72.
16. Lepist EL, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and the risk of hospitalization for first myocardial infarction in patients with chronic bronchitis. J Pediatr Hematol Oncol. 2006;173:1114-21.
17. Pichard A, Campbell TJ. Airway T-regulatory cells by gastrointestinal stimulation as substrates in sandwich-cultured human hepatocytes. J Clin Pharmacol. 2011;51:1243-51.
18. Collet JP, Sharp P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IT Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by the Bacterial Extract OM-85. Am J Respir Crit Med. 1997;156:1719-24.
19. Li Z, Zheng Y, Fan P, et al. Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chin Med J (Engl). 2008;118:734-8.
20. Solt M, Mutterlin R, Cozma G, et al. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration. 2007;74:36-42.
21. Pan J, Jiang XG, Guo J, et al. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Int J Clin Pharmacol. 2015;95:139–44.
22. Shamane A, Moret C, Zhou Y, et al. COPD exacerbation frequency and its associated costs: an economic evaluation and costs. Int J Chron Obstruct Pulmon Dis. 2016;10:1609–26.
23. Vla V, Allinson R, Beck E, et al. Impact of an integrated disease management program in reducing exacerbations in patients with chronic obstructive pulmonary disease: the STOP COPD trial. Thorax. 2012;67:51-1.
24. Diliberti L, Fernández AM, Buttin J-M, et al. Pan-American clinical practice guidelines for medical management of acute and chronic rhinosinusitis. Presented at the American Association of Otolaryngology – Head and Neck Surgery (AAO-HNS) annual meeting. Available at: www.aao.org/publications/Papers/AOAHNS/aaos2012/1521/sf.pdf (accessed 3 February 2019).
25. EMEA, Report EMEA/57476/2009. The bacterial challenge: time to react. Available at: https://redc.europa.eu/sites/portal/files/media/3e87bbe7-0538-4987-928d-005f911f8d0d/2009_FINAL-revised-20-Nov_WMS.pdf (accessed 3 February 2019).
26. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2016. Available at: https://ecdc.europa.eu/sites/portal/files/media/9e5f5e5e-9d9d-399b-005f911f8d0d/2016_Final_report.pdf (accessed 30 September 2019).
27. Williams MR, Greene S, Naik G, et al. Antibiotic prescribing quality for children in primary care: an observational study. Br J Gen Pract. 2010;60:96–9.
28. Manglay G, Steenhoff MP, Gopalkrishnan S, et al. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2015;13:116-25.
29. Pietz MN, Taccioni E, Welte B. Antibiotic Stewardship 2.0: Individualization of therapy. Intern Med. 2016:55:1886-92.
30. Navarro S, Cossalter G, Chiavari C, et al. The oral administration of imperatorin alleviates asthma by the recruitment of regulatory T cells in patients with allergic asthma. PLoS ONE. 2011;6:e15435.
31. Brown HH, Clarke T. The regulation of host defences to infection by the microbiota. Immunobiol. 2017;191:1-6.